Raymond James upgrades Aveanna Healthcare stock on valuation By Investing.com

Raymond James upgraded Aveanna Healthcare to Strong Buy from Outperform, maintaining a $13 price target (implying ~11.7x 2027 EBITDA) while the stock trades at $6.62 (down ~9% over the past week). Aveanna reported Q4 2025 revenue of $662.5M (+27.4% YoY) that beat expectations by 5.06% and EPS that beat by 30.77%; the company has 13 consecutive quarters of beats. Valuation context: company EV/EBITDA ~10x, Raymond James cites precedent transactions at ~8–10x and views 7.6x 2027 EBITDA as a discount; Jefferies trimmed its PT to $10 from $12.50 but kept a Buy rating.

Analysis

Private-equity appetite for home-health platforms is the structural tailwind underpinning the stock-level rerating here: sponsor bids create an asymmetric payoff for smaller, acquisitive operators because strategic buyers pay control premiums to consolidate administrative and payor contracts. That dynamic amplifies for companies with recurring FCF and visible margin expansion potential, but it also creates dispersion — firms with weaker payer mixes or higher staff-cost sensitivity will not see the same multiple uplift.

Near-term catalysts that will move the tape are M&A flow and sequential margin beats; both can materialize inside 3–12 months as deal processes and guidance revisions play out. Key risks that can reverse the trade are reimbursement-policy headlines, a sharp rise in caregiver wage inflation, or a credit market repricing that removes sponsor financing capacity — any of which can compress takeout multiples quickly.

Tactically, the cleanest way to express the asymmetry is a concentrated, hedged position sized for event risk: a long exposure to under-followed home-health small caps hedged by index-healthcare or larger provider shorts to limit sector beta. Liquidity and option skew favor buying long-dated calls or collars instead of naked equity for a 6–12 month M&A window.

Contrarian read: the market is pricing a binary M&A outcome but underestimates correlated operational risks; if labor inflation outpaces reimbursement fixes, multiple convergence toward strategic comps will stall. Monitor three data points as early warnings — same-store visit intensity, incremental payer contract renewals, and quarterly SG&A-to-revenue trajectory — before adding material exposure.

Key Decisions for Investors

• AVAH — Initiate a 1% NAV long position (equity) with a 1% add-on if EV/EBITDA remains >20% below precedent-transaction comps after the next quarterly report; hedge with a 6–12 month put (cost ~2–4% notional). Target: 50–100% upside on a takeout within 12 months; downside: limit loss to 25% via stop or hedge.
• Pair trade — Long AVAH (0.8x notional) / Short EHC (0.5x notional) for 6–12 months to capture multiple convergence; expected payoff 30–60% if small-cap premium re-rates toward strategic comps. Risk: correlated industry shock (reimbursement/labor) can cause both legs to fall; cap max drawdown at 20% via dynamic hedge.
• Options play — Buy 9–12 month AVAH calls (delta ~0.40–0.60) sized at 0.5% NAV to lever takeout odds; set a profit-taking rule at +100% premium or on confirmed bid interest. Loss limited to option premium (~0.5% NAV).
• Risk-off trigger — If quarterly guidance shows SG&A deleverage or same-store patient visits down >5% sequentially, close long exposure and rotate into large-cap, diversified healthcare insurers (UNH) as safe-haven within 1–3 months.